This trial is testing whether a new cancer drug is safe for people with HER2+ cancer.
- HER2-positive Breast Cancer
- HER2 Positive Metastatic Breast Cancer
1 Primary · 0 Secondary · Reporting Duration: Up to 20 months
Awards & Highlights
3 Treatment Groups
1 of 3
1 of 3
1 of 3
20 Total Participants · 3 Treatment Groups
Primary Treatment: 89Zr-ss-pertuzumab PET/CT · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent is the population involved in this research endeavor?
"Affirmative, according to clinicaltrials.gov the trial is actively recruiting participants who were initially posted on November 30th 2020 and last edited September 13th 2022. At this time, 20 individuals are being recruited from two distinct sites." - Anonymous Online Contributor
Has the FDA given authorization for 89Zr-ss-pertuzumab PET/CT imaging?
"Taking into account the limited amount of safety and efficacy data, our team at Power have assigned 89Zr-ss-pertuzumab PET/CT a score of 1 on their scale from 1 to 3." - Anonymous Online Contributor
Has recruitment for this medical trial commenced?
"According to the records found on clinicaltrials.gov, enrollment for this medical research is ongoing. It was initially posted in November of 2020 and its details were most recently edited in September 2022." - Anonymous Online Contributor
Is this a pioneering endeavor in its field?
"According to current information, there are 90 active studies involving 89Zr-ss-pertuzumab PET/CT across 1397 cities and 62 countries. This medical technology was first tested in 2008 when Hoffmann La Roche sponsored a Phase 2 trial that included 720 patients. Over the last 12 years, 69 different trials utilizing this method have been concluded." - Anonymous Online Contributor
What previous experiments have included 89Zr-ss-pertuzumab PET/CT as one of their tools?
"The first study of 89Zr-ss-pertuzumab PET/CT occured in 2008 at SCRI Tennessee Oncology Chattanooga. Over the last 12 years, 69 trials have been concluded with 90 still underway; particularly, many are located around Newport Beach, California." - Anonymous Online Contributor
To what maladies is 89Zr-ss-pertuzumab PET/CT commonly prescribed?
"89Zr-ss-pertuzumab PET/CT is usually employed to treat the therapeutic procedure in question, but can also provide relief from brca1 gene, inflammatory breast cancer (ibc), and malignant neoplasms." - Anonymous Online Contributor